Body Composition Changes over the Menopausal Transition in Women With and Without HIV.

Understanding and addressing socio-cultural barriers to medical male circumcision in traditionally non-circumcising rural communities in sub-Saharan Africa.

Division of Rheumatology - Pre-Clinic Conference

Invited commentary: Discrimination--an emerging target for reducing risk of cardiovascular disease?

Guidelines for sedation and anesthesia in GI endoscopy.

Effects of antiresorptive treatment on nonvertebral fracture outcomes.

ASSOCIATION BETWEEN LARGE AND SMALL ARTERY ELASTICITY AND NT-PRO B-TYPE NATRIURETIC PEPTIDE: RESULTS OF THE MULTI-ETHNIC STUDY FOR ATHEROSCLEROSIS.

The Impact of Carbohydrate Restriction and Nutritional Ketosis on Cardiovascular Health.

Eating Disorders: Identification and Management in General Medical and Psychiatric Settings.

A New Era in Cardiac Rehabilitation Delivery: Research Gaps, Questions, Strategies, and Priorities.

A framework for the analysis of acoustical cardiac signals.

Stem cells and breast cancer: A field in transit.

Alex Smith Serves as Panelist for "Social Media as a Tool for Career Development" Webinar

Alex Smith, MD is part of a panel presenting a national webinar about "Social Media as a Tool for Career Development" on March 17, 2021.

The goals of the webinar are to provide useful information on:

   1.  Considering the tradeoffs of engaging in social media for professional reasons

   2.  How to use social media to advance your research and your career

   3.  How social media success can be used to expand the reach of your work and build your national profile

   4.  How to understand social media metrics

   5.  How to build an audience

Register using the following link: https://us02web.zoom.us/webinar/register/WN_0W9Ln6-ERIaQDWKQj9JYlw

Visit the RCCN website to learn more: https://www.rccn-aging.org/march-17-rccn-webinar

Angiopoietin like protein 4 expression is decreased in activated macrophages.

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.